CN111249527A - Soft tissue filler of platelet-rich plasma and preparation method thereof - Google Patents
Soft tissue filler of platelet-rich plasma and preparation method thereof Download PDFInfo
- Publication number
- CN111249527A CN111249527A CN201811483421.9A CN201811483421A CN111249527A CN 111249527 A CN111249527 A CN 111249527A CN 201811483421 A CN201811483421 A CN 201811483421A CN 111249527 A CN111249527 A CN 111249527A
- Authority
- CN
- China
- Prior art keywords
- autologous
- soft tissue
- svf
- prp
- rich plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004623 platelet-rich plasma Anatomy 0.000 title claims abstract description 46
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 26
- 239000000945 filler Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 19
- 239000000463 material Substances 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims abstract description 33
- 238000002156 mixing Methods 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 229920002674 hyaluronan Polymers 0.000 claims description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 102000029816 Collagenase Human genes 0.000 claims description 6
- 108060005980 Collagenase Proteins 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 229960002424 collagenase Drugs 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 4
- 229960001008 heparin sodium Drugs 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims 2
- 230000004083 survival effect Effects 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 230000007547 defect Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 210000000130 stem cell Anatomy 0.000 abstract description 3
- 230000001815 facial effect Effects 0.000 abstract description 2
- 230000000250 revascularization Effects 0.000 abstract description 2
- 238000007493 shaping process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000003796 beauty Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3616—Blood, e.g. platelet-rich plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a soft tissue filler of platelet rich plasma, which comprises autologous PRP, autologous SVF and a scaffold material, and is prepared by mixing the autologous PRP, the autologous SVF and the scaffold material. The support material provides a reliable three-dimensional growth environment for SVF, improves the survival rate of adipose-derived stem cells, and promotes the regeneration of adipose-derived cells, and on the other hand, the support material realizes the repair of soft tissue defects by virtue of physical space occupation, so that the mixture can promote the regeneration of tissues while realizing the repair of tissue defects. The soft tissue filler prepared by the invention has the advantages of easy revascularization after injection, slight inflammatory reaction, safety and reliability, and is suitable for soft tissue filling, sunken deformity caused by soft tissue defect repair, and facial and body beautifying and shaping.
Description
Technical Field
The invention belongs to the technical field of plastic cosmetology, and particularly relates to a soft tissue filler of Platelet Rich Plasma (PRP) and a preparation method thereof.
Background
With the improvement of living standard, people have higher and higher requirements on the appearance of the temperament, and the anti-wrinkle effect has become the demand of more and more people. People have higher requirements on the safety of related products while pursuing beauty. Traditional subcutaneous injection of hyaluronic acid can achieve temporary wrinkle removal, but the effect is not durable enough, and once the implant material degrades, wrinkles and depressions reappear.
Autologous fat, which is derived from autologous tissue, does not have a risk of immunological rejection, has good compatibility, and is considered as the most ideal orthopedic implant, but the greatest problem after fat transplantation is that the survival rate is too low, fat liquefaction easily occurs, the effect is maintained for a short time, and the application of fat transplantation is severely limited.
Chinese patent CN 104739862A discloses a mixture of PRP and SVF, which is directly mixed for cosmetic injection filling. The composition can improve certain filling effect compared with the single use of PRP, but PRP can not provide reliable three-vitamin long space for SVF, and has low cell survival rate and short wrinkle repair duration. In addition, the PRP source of the invention is cord blood, not autologous blood, and also risks of viral transmission and immune rejection.
In summary, in the aspect of cosmetic injection filling materials, a pure sodium hyaluronate filling agent, autologous fat transplantation filling and a filling agent mixed with autologous fat extract and PRP are all applied, and the integral injection cosmetic market is mixed with fish dragons, but products with good true compatibility, long maintenance time and few complications are not abundant. In combination with the appeal of the beauty seeking people, the market needs an injection beauty filling product with high safety, good compatibility and long lasting time.
Disclosure of Invention
In view of the above problems, the present invention provides a soft tissue filler of Platelet Rich Plasma (PRP), which overcomes the disadvantages of the conventional hyaluronic acid alone and PRP with short filling duration or poor tissue regeneration promoting ability. Also provides a preparation method of the filler.
One technical scheme of the invention is that the soft tissue filler comprises autologous PRP, autologous SVF and a scaffold material; the scaffold material is a biodegradable material or an autologous component which can be accepted by organisms.
The SVF is a vascular stromal component (vascular stromal) in adipose tissue, is a cell mixture, comprises stromal cells, high-concentration adipose-derived stem cells, blood cells such as vascular endothelial cells, white blood cells and red blood cells, and can promote growth factors of the surrounding environment such as: PDGF, EGF, FGF, VEGF, IGF and the like are secreted, so that the angiogenesis function is promoted, and the survival rate of various cells is improved; on the other hand, SVF has an immunomodulatory effect and is able to reduce inflammatory responses.
The scaffold material can be selected from commercialized products or prepared by self, and is made of biodegradable materials or self-components acceptable by organisms, and the material comprises any one or combination of several of collagen, hyaluronic acid, sodium hyaluronate, polylactic acid, hydroxyapatite and self fat.
The bracket material is a common clinical injection filling material, and is safe and reliable. The use of the scaffold material can provide support and space for the new cells, and is convenient for the growth of the cells and the growth of new blood vessels; in the initial stage of transplantation, the scaffold material can play a good auxiliary type effect, and along with the metabolic absorption of the scaffold material, the new tissue fills the original space of the scaffold material, so that the overall filling effect and the tissue survival rate are improved.
Preferably, the number of viable cells of autologous SVF per 10ml of soft tissue filler is 106-107(ii) a The number of platelets was 105-107(ii) a The volume ratio of the autologous PRP to the autologous SVF is 1:1, and the volume of the scaffold material is 1-4 times of the total volume of the autologous PRP and the autologous SVF.
The invention also provides a preparation method of the soft tissue filler, which comprises the following steps:
step 1, preparation of autologous PRP
Adding an anticoagulant into the blood of a subject, and centrifuging the blood for 6-10min at a centrifugal force of 450 Xg (200-); sucking the upper plasma layer into a new centrifuge tube, centrifuging for 5-9min at 650-.
Step 2, preparation of autologous SVF
Standing the extracted adipose tissues at room temperature, removing a liquid part, adding an equal volume of physiological saline for cleaning, centrifuging at the temperature of 21 ℃ for 3-10min at 1500r/min for 1000-. Adding collagenase solution prepared by normal saline with the same volume, oscillating and digesting for 30-60min at constant temperature, collecting digestive juice, centrifuging for 5-10min at 21 ℃ and 1200r/min, removing supernatant, taking cell sediment, adding normal saline, centrifuging for 5-10min at 21 ℃ and 1500r/min, taking cell sediment again, and resuspending by normal saline to obtain the autologous SVF.
Step 3, adding a bracket material
Mixing the autologous PRP, the autologous SVF and the scaffold material to obtain the composite material.
Preferably, the anticoagulant in step 1 is one or two of heparin sodium and sodium citrate.
Preferably, the number of platelets in the PRP of step 1 is preferably 105-108。
Preferably, the total number of viable cells of the SVF of step 2 is 106-108。
Preferably, the enzyme activity of the collagenase obtained in the step 2 is 50-300U/mL, and the digestion time is 25-40 min.
Preferably, CaCl is added to the autologous PRP prior to mixing in step 32A solution; the CaCl is2The concentration of the solution is 0.05M-2M, and the adding proportion is that 50 mu LCaCl is added into each 1mL of PRP2And (3) solution.
The support material of the soft tissue filler provides a reliable three-dimensional growth environment for SVF, improves the survival rate of adipose-derived stem cells, promotes the regeneration of adipose-derived cells, and on the other hand, realizes the physical space occupying effect of the support material to realize the repair of soft tissue defects; SVF reduces inflammatory reaction through immune regulation, secretes various factors to promote angiogenesis, and establishes blood supply for the repair part; the growth factor in PRP can control inflammation, relieve pain during treatment, promote the generation of subcutaneous collagen, elastic fiber and colloid, promote tissue regeneration, and accelerate tissue repair. The mixture can repair tissue defect and promote tissue regeneration.
The soft tissue filler obtained by the invention has the advantages of easy revascularization after injection, slight inflammatory reaction, safety and reliability, and is suitable for soft tissue filling, depression deformity caused by soft tissue defect repair, and facial and body beautifying shaping.
Drawings
FIG. 1 shows HE slices (magnification 100 times) of different preparations implanted subcutaneously into rats of 26 weeks with Ruilan 2 hyaluronic acid as scaffold material, (a) scaffold + SVF + PRP, (b) scaffold + PRP, (c) scaffold + SVF;
fig. 2 shows HE slices (magnification 100 times) of rats implanted subcutaneously for 26 weeks with fat as a scaffold material, (a) scaffold + SVF + PRP, (b) scaffold + PRP, (c) scaffold + SVF;
FIG. 3 is a HE slice diagram of a rat subcutaneously implanted with 26 weeks after mixing PRP and SVF formulations with Ruilan 2 hyaluronic acid as a scaffold material;
FIG. 4 is a view of HE sections of rats subcutaneously implanted for 26 weeks after mixing PRP and SVF preparations with fat as a scaffold material;
FIG. 5 is a view of HE sections of rats subcutaneously implanted for 26 weeks after mixing PRP and SVF formulations;
FIG. 6 is a graph of HE slices of Railan 2 hyaluronic acid rats implanted subcutaneously for 26 weeks;
fig. 7 is a view of HE sections of fat rats implanted subcutaneously for 26 weeks.
Detailed Description
The present invention will be described in further detail with reference to the drawings and the following detailed description, but the present invention is not limited to these embodiments.
Example 1
Step one, preparation of PRP
20mL of autologous blood was collected, and sodium citrate anticoagulant (2.2 mL of 3.8% aqueous sodium citrate solution) was added. First, whole blood was centrifuged at 250 Xg for 8 min; sucking the upper plasma layer into a new centrifuge tube at 700 Xg, and centrifuging for 6 min twice; removing part of plasma, and resuspending the pellet in the remaining plasma to obtain PRP with a volume of about 1.0 mL. The number of platelets in PRP was 8.2X 108And (4) respectively.
Step two, preparation of SVF
Extracting 20mL of adipose tissue, standing for 20 min at room temperature, removing tumescent liquid in the anesthesia process to further purify fat, and removing a liquid part to obtain 15mL of fat particles; adding 15mL of normal saline for washing, centrifuging at 1200r/min at 21 ℃ for 6 min, and removing liquid part to obtain 10mL of solid fat particles. Adding 10mL of collagenase solution (200U/mL) prepared by normal saline, carrying out shake digestion at constant temperature of 37 ℃ for 40min, collecting the digestion solution, centrifuging at 1000r/min and 21 ℃ for 8 min, removing the supernatant, taking cell sediment, adding 6 mL of normal saline, centrifuging at 800r/min and 21 ℃ for 6 min, taking cell sediment again, and carrying out resuspension by using 1mL of normal saline to obtain the fat SVF. Counting with a cell counter to obtain total cell number of 4.2 × 107The cell survival rate is 89 percent, and the total number of living cells is 3.7 multiplied by 107And (4) respectively.
Step three, mixing the preparation
The stent material of the present example was selected from commercially available Rayleigh blue®2 modified sodium hyaluronate gel for injection.
First, 0.1M CaCl was added to the PRP2Solution (50 muL CaCl added per 1ml PRP)2Solution of CaCl2For activating PRP to form a gel), 0.5mL of the solution was taken, mixed with 0.5mL of SVF, and finally mixed with 1mL of rayleigh blue®2, mixing the hyaluronic acid stent by adopting a luer syringe. The obtained preparation has platelet number of 4.1 × 108Number of viable cells of SVF was 2.1X 107And (4) respectively.
As shown in fig. 1, with the addition of the scaffold material, blood circulation around the implant was good and new blood vessels were clearly visible. As can be seen from FIGS. 3, 5 and 6, hyaluronic acid provides a three-dimensional space for SVF cells, local blood circulation is good, and the survival rate of the cells is high; and with hyaluronic acid degradation, PRP and SVF cells have obvious effect of promoting regeneration of peripheral tissues, and the overall maintenance time is longer.
Example 2
Step one, preparation of PRP
20mL of autologous blood was collected and anticoagulant heparin sodium (0.4 mL of 1% heparin sodium solution) was added. First, whole blood is centrifuged at 200 Xg for 10 min; sucking the upper plasma layer into a new centrifugal tube, centrifuging for 5min at 800 Xg for the second time; removing part of plasma, and resuspending the pellet in the remaining plasma to obtain PRP with a volume of about 1.0 mL. The platelet count in PRP was 11.4X 108And (4) respectively.
Step two, preparation of SVF
Extracting 40mL of adipose tissue, standing for 20 min at room temperature, and removing liquid to obtain 30mL of fat particles; adding 30mL of physiological saline for washing, centrifuging at 1200r/min at 21 ℃ for 6 min, and removing liquid part to obtain 20mL of solid fat particles.
Taking 10mL of solid fat particles, adding 10mL of collagenase solution (300U/mL) prepared by normal saline, carrying out constant-temperature shaking digestion at 37 ℃ for 25min, collecting digestion solution, centrifuging at 800r/min and 21 ℃ for 10min, removing supernatant, taking cell precipitate, adding 8 mL of normal saline, centrifuging at 1200r/min and 21 ℃ for 5min, taking cell precipitate again, and carrying out resuspension by using 2.0 mL of normal saline to obtain the fat SVF. Counting with a cell counter to obtain total cell number of 10.1 × 107The cell survival rate is 85 percent, and the total number of living cells is 8.8 multiplied by 107And (4) respectively.
Step three, mixing the preparation
The scaffold material selected in this example is autologous fat, that is, solid fat particles prepared in step two.
First, 0.1M CaCl was added to the PRP2Solution (50 muL CaCl added per 1ml PRP)2Solution), 0.5mL of which was taken, mixed with 0.5mL of SVF and finally with 4mL of autologous fat particles, all mixed using a luer syringe. The obtained preparation has platelet number of 5.7 × 108Number of viable cells of SVF was 2.5X 107And (4) respectively.
As shown in FIG. 2, the scaffold material provides three-dimensional space for SVF to grow cells. As can be seen from fig. 4, 5 and 7, the purified fat is used as the material of the scaffold, so that the survival rate of fat cells is higher, the degree of inflammatory reaction is lower, the in vivo maintenance time is longer, and the fat filling effect is improved.
Claims (10)
1. A soft tissue bulking agent of platelet rich plasma comprising autologous PRP, autologous SVF and scaffold material; the scaffold material is any one or a combination of more of collagen, hyaluronic acid, sodium hyaluronate, polylactic acid, hydroxyapatite and autologous fat.
2. The platelet rich plasma soft tissue filler of claim 1, wherein the scaffold material is sodium hyaluronate or autologous fat.
3. The platelet rich plasma soft tissue filler according to claim 2, wherein the number of viable cells of autologous SVF per 10ml of the soft tissue filler is 106-107(ii) a The number of platelets was 105-107(ii) a The volume ratio of the autologous PRP to the autologous SVF is 1:1, and the volume of the scaffold material is 1-4 times of the total volume of the autologous PRP and the autologous SVF.
4. A method of preparing the soft tissue filler of platelet rich plasma according to claim 1, comprising the steps of:
step 1, preparation of autologous PRP
Adding anticoagulant into the blood of a subject, and centrifuging the blood at 450 Xg at 200-; sucking the upper plasma layer into a new centrifugal tube, centrifuging for 5-9min at 650-;
step 2, preparation of autologous SVF
Standing the extracted adipose tissues at room temperature, removing a liquid part, adding equal volume of normal saline for cleaning, centrifuging at 21 ℃ for 3-10min at 1500r/min for 1000-; adding collagenase solution prepared by normal saline with the same volume, oscillating and digesting for 30-60min at constant temperature, collecting digestive juice, centrifuging for 5-10min at 21 ℃ and 1200r/min, removing supernatant, taking cell sediment, adding normal saline, centrifuging for 5-10min at 21 ℃ and 1500r/min, taking cell sediment again, and resuspending by normal saline to obtain autologous SVF;
step 3, adding a bracket material
Mixing the autologous PRP, the autologous SVF and the scaffold material to obtain the composite material.
5. The method for preparing soft tissue filler of platelet rich plasma according to claim 4, wherein the anticoagulant in step 1 is one or two of heparin sodium and sodium citrate.
6. The method for preparing soft tissue filler of platelet rich plasma according to claim 4, wherein the number of platelets in the autologous PRP prepared in step 1 is 105-108。
7. The method of claim 4, wherein the autologous SVF obtained in step 2 has a total viable cell count of 106-108。
8. The method for preparing soft tissue bulking agent of platelet rich plasma according to claim 4, wherein the enzyme activity of collagenase in step 2 is 50-300U/mL and the digestion time is 25-40 min.
9. The method for preparing a soft tissue filler of platelet rich plasma according to claim 4, wherein the scaffold material in step 3 is sodium hyaluronate or autologous fat.
10. The method of claim 4, wherein CaCl is added to the autologous PRP prior to mixing in step 32A solution; the CaCl is2The concentration of the solution is 0.05M-2M, and the addition proportion is that 50 mu LCaCl is added into each 1mL of PRP2And (3) solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811483421.9A CN111249527A (en) | 2018-12-03 | 2018-12-03 | Soft tissue filler of platelet-rich plasma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811483421.9A CN111249527A (en) | 2018-12-03 | 2018-12-03 | Soft tissue filler of platelet-rich plasma and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111249527A true CN111249527A (en) | 2020-06-09 |
Family
ID=70923858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811483421.9A Pending CN111249527A (en) | 2018-12-03 | 2018-12-03 | Soft tissue filler of platelet-rich plasma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111249527A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111778209A (en) * | 2020-08-04 | 2020-10-16 | 博品(上海)生物医药科技有限公司 | SVF extraction reagent, preparation method thereof and application thereof in SVF cell extraction |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102205147A (en) * | 2011-05-16 | 2011-10-05 | 中国人民解放军第四军医大学 | Transplanting material of fat granule tissues compounded with SVFs (Stromal Vascular Fractions) and PRFs (Platelet-Rich Fibrins) as well as preparation method and application thereof |
| CN102573943A (en) * | 2009-10-23 | 2012-07-11 | 世元世龙技术株式会社 | Composition for inducing tissue regeneration by activating platelet-rich plasma (PRP), and method for manufacturing same |
| US20140227240A1 (en) * | 2013-02-08 | 2014-08-14 | Laser Spine Institute, Llc | Regeneration of Spinal Discs |
| CN104739862A (en) * | 2015-04-03 | 2015-07-01 | 广州赛莱拉干细胞科技股份有限公司 | Composition and application thereof |
| CN104984399A (en) * | 2015-07-29 | 2015-10-21 | 西安芙金细胞科技有限公司 | Preparation method of biological scaffold material and SVF assistant adipose tissue |
| WO2015159308A2 (en) * | 2014-04-16 | 2015-10-22 | Pradeep Mahajan | Osteoinductive formulation and preparation thereof |
| CN106823002A (en) * | 2016-12-26 | 2017-06-13 | 广州赛莱拉干细胞科技股份有限公司 | A kind of anti-aging face filler and preparation method thereof |
| CN108653329A (en) * | 2018-05-28 | 2018-10-16 | 广东唯泰生物科技有限公司 | It is a kind of to be used to treat drug of osteoarthritis and preparation method thereof |
| CN108704164A (en) * | 2018-05-17 | 2018-10-26 | 广东芙金干细胞再生医学有限公司 | A kind of injection cell auxiliary autologous fat transplantation object and preparation method thereof |
-
2018
- 2018-12-03 CN CN201811483421.9A patent/CN111249527A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573943A (en) * | 2009-10-23 | 2012-07-11 | 世元世龙技术株式会社 | Composition for inducing tissue regeneration by activating platelet-rich plasma (PRP), and method for manufacturing same |
| CN102205147A (en) * | 2011-05-16 | 2011-10-05 | 中国人民解放军第四军医大学 | Transplanting material of fat granule tissues compounded with SVFs (Stromal Vascular Fractions) and PRFs (Platelet-Rich Fibrins) as well as preparation method and application thereof |
| US20140227240A1 (en) * | 2013-02-08 | 2014-08-14 | Laser Spine Institute, Llc | Regeneration of Spinal Discs |
| WO2015159308A2 (en) * | 2014-04-16 | 2015-10-22 | Pradeep Mahajan | Osteoinductive formulation and preparation thereof |
| CN104739862A (en) * | 2015-04-03 | 2015-07-01 | 广州赛莱拉干细胞科技股份有限公司 | Composition and application thereof |
| CN104984399A (en) * | 2015-07-29 | 2015-10-21 | 西安芙金细胞科技有限公司 | Preparation method of biological scaffold material and SVF assistant adipose tissue |
| CN106823002A (en) * | 2016-12-26 | 2017-06-13 | 广州赛莱拉干细胞科技股份有限公司 | A kind of anti-aging face filler and preparation method thereof |
| CN108704164A (en) * | 2018-05-17 | 2018-10-26 | 广东芙金干细胞再生医学有限公司 | A kind of injection cell auxiliary autologous fat transplantation object and preparation method thereof |
| CN108653329A (en) * | 2018-05-28 | 2018-10-16 | 广东唯泰生物科技有限公司 | It is a kind of to be used to treat drug of osteoarthritis and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111778209A (en) * | 2020-08-04 | 2020-10-16 | 博品(上海)生物医药科技有限公司 | SVF extraction reagent, preparation method thereof and application thereof in SVF cell extraction |
| CN111778209B (en) * | 2020-08-04 | 2023-02-28 | 北京博品贝莱生物医药科技有限公司 | SVF extraction reagent, preparation method thereof and application thereof in SVF cell extraction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ho et al. | Current advancements and strategies in tissue engineering for wound healing: a comprehensive review | |
| US20210346587A1 (en) | New standardizations & medical devices for the preparation of platelet rich plasma (prp) or bone marrow concentrate (bmc) alone or in combination with hyaluronic acid | |
| Modarressi | Platlet rich plasma (PRP) improves fat grafting outcomes | |
| RU2531046C2 (en) | Rapid preparation and use of artificial tissues and frames as individual implants | |
| CN104984399A (en) | Preparation method of biological scaffold material and SVF assistant adipose tissue | |
| WO2018065092A1 (en) | Compositions comprising adjustable concentrations of growth factors derived from blood serum and clot hypoxia-conditioned medium and methods of their production | |
| AU2010210141A1 (en) | Method and means for producing tissues and tissues obtained | |
| CN102284082B (en) | Facial fibrous protein composite filled and positioned in subcutaneous soft tissues, and preparation method thereof | |
| JP2021512680A (en) | A bio-ink composition for a dermis regeneration sheet, a method for producing a custom-made dermis regeneration sheet using the bio-ink composition, and a custom-made dermis regeneration sheet produced using the production method. | |
| JP2009235004A (en) | Method for promoting cellular tissue increase and method for ameliorating skin problem, and kit used in these methods | |
| GARCIA et al. | Adipose tissue-derived stem cell autologous grafts: a new approach to application in the treatment of burn victims and reconstructive plastic surgery | |
| CN111249527A (en) | Soft tissue filler of platelet-rich plasma and preparation method thereof | |
| US20130072903A1 (en) | Adipose Tissue Graft for Wound Healing | |
| Gennai et al. | Superficial enhanced fluid fat injection (SEFFI and MicroSEFFI) in facial rejuvenation | |
| US11564943B2 (en) | Platelet concentrate for increase of cell regeneration and cell growth | |
| Shalaby et al. | Correction of Depressed Scars with PRP Enriched Fat Graft | |
| JP5186050B1 (en) | Composition for promoting subcutaneous tissue and subcutaneous fat tissue increase | |
| Ren et al. | Fat grafting with adipose stem cells: the successes and challenges | |
| Burgess | Soft tissue augmentation | |
| Prantl et al. | Facial Rejuvenation with Concentrated Lipograft—A 12 Month Follow-Up Study. Cells 2021, 10, 594 | |
| Sultan et al. | Platelet-rich Fibrin and its Application in Dentistry: An Institutional Experience | |
| Madnani et al. | Emerging Techniques: Platelet-Rich Plasma Therapy | |
| Saluja et al. | Use of platelet-rich fibrin a backbone in facial plastic surgery and wound healing: A review of literature | |
| Alessandro et al. | Guided Superficial Enhanced Fluid Fat Injection (SEFFI) Procedures for Facial Rejuvenation: An Italian Multicenter Retrospective Case Reports | |
| Sobajima et al. | Adipose-derived stem cells: Use in clinical medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200609 |
|
| RJ01 | Rejection of invention patent application after publication |